The Anti-Tumor Effect of Lactococcus lactis Bacteria-Secreting Human Soluble TRAIL Can Be Enhanced by Metformin Both In Vitro and In Vivo in a Mouse Model of Human Colorectal Cancer
Open Access
- 15 June 2021
- Vol. 13 (12), 3004
- https://doi.org/10.3390/cancers13123004
Abstract
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) induces apoptosis of many cancer cells, including CRC cells, being non-harmful for normal ones. However, recombinant form of human TRAIL failed in clinical trial when administered intravenously. To assess the importance of TRAIL in CRC patients, new form of TRAIL delivery would be required. Here we used genetically modified, non-pathogenic Lactococcus lactis bacteria as a vehicle for local delivery of human soluble TRAIL (hsTRAIL) in CRC. Operating under the Nisin Controlled Gene Expression System (NICE), the modified bacteria (L. lactis(hsTRAIL+)) were able to induce cell death of HCT116 and SW480 human cancer cells and reduce the growth of HCT116-tumor spheres in vitro. This effect was cancer cell specific as the cells of normal colon epithelium (FHC cells) were not affected by hsTRAIL-producing bacteria. Metformin (MetF), 5-fluorouracil (5-FU) and irinotecan (CPT-11) enhanced the anti-tumor actions of hsTRAIL in vitro. In the NOD-SCID mouse model, treatment of subcutaneous HCT116-tumors with L. lactis(hsTRAIL+) bacteria given intratumorally, significantly reduced the tumor growth. This anti-tumor activity of hsTRAIL in vivo was further enhanced by oral administration of MetF. These findings indicate that L. lactis bacteria could be suitable for local delivery of biologically active human proteins. At the same time, we documented that anti-tumor activity of hsTRAIL in experimental therapy of CRC can be further enhanced by MetF given orally, opening a venue for alternative CRC-treatment strategies.Funding Information
- Narodowe Centrum Nauki (UMO-2014/15/B/NZ5/03484)
- Horizon 2020 MSCA-RISE program ("CANCER" (GA no.777682))
This publication has 92 references indexed in Scilit:
- Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testingCell Death & Disease, 2013
- Resistance to TRAIL in non-transformed cells is due to multiple redundant pathwaysCell Death & Disease, 2013
- Cancer‐generated lactic acid: a regulatory, immunosuppressive metabolite?The Journal of Pathology, 2013
- Epigenetics and colorectal cancerNature Reviews Gastroenterology & Hepatology, 2011
- Oxaliplatin Sensitizes Human Colon Cancer Cells to TRAIL Through JNK-Dependent Phosphorylation of Bcl-xLGastroenterology, 2011
- Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteersThe ISME Journal, 2011
- Hereditary and Familial Colon CancerGastroenterology, 2010
- Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05Journal of Clinical Oncology, 2010
- Tumor-targeted delivery of biologically active TRAIL proteinCancer Gene Therapy, 2010
- Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in miceBritish Journal of Cancer, 2009